This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

HAEMATO Valuation

Q: What is the Fair Price of HAEK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

HAEK (€15) is trading below our estimate of [[fair value]] (€27.73)

Is HAEK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HAEK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HAEK (€15) is trading below our estimate of fair value (€27.73)

Significantly Below Fair Value: HAEK is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HAEK?

Key metric: As HAEK is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HAEK. This is calculated by dividing HAEK's market cap by their current earnings.
What is HAEK's PE Ratio?
PE Ratio	10.1x
Earnings	€9.61m
Market Cap	€96.71m

HAEK key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.3x
Enterprise Value/EBITDA	8.9x
PEG Ratio	1.7x

Price to Earnings Ratio vs Peers

How does HAEK's PE Ratio compare to its peers?

The above table shows the PE ratio for HAEK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	23.6x
ILM1 Medios	26x	43.9%	€334.7m
LIK LIMES Schlosskliniken	23.3x	n/a	€99.7m
PUS PULSION Medical Systems	26.7x	n/a	€134.4m
M12 M1 Kliniken	18.3x	17.5%	€307.1m
HAEK HAEMATO	10.1x	5.8%	€96.7m

Price-To-Earnings vs Peers: HAEK is good value based on its Price-To-Earnings Ratio (10.1x) compared to the peer average (21.2x).

Price to Earnings Ratio vs Industry

How does HAEK's PE Ratio compare vs other companies in the European Healthcare Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: HAEK is good value based on its Price-To-Earnings Ratio (10.1x) compared to the European Healthcare industry average (18.5x).

Price to Earnings Ratio vs Fair Ratio

What is HAEK's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HAEK PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	10.1x
Fair PE Ratio	17.6x

Price-To-Earnings vs Fair Ratio: HAEK is good value based on its Price-To-Earnings Ratio (10.1x) compared to the estimated Fair Price-To-Earnings Ratio (17.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

-1.0%

-38.8%

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

-6.1%

16.0%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

0.5%

-82.5%